Patents by Inventor Maria A. Bednarek

Maria A. Bednarek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Melanin-concentrating hormone analogs
    Patent number: 7220720
    Abstract: The present invention features truncated MCH analogs active at the MCH receptor. The truncated MCH analogs are optionally modified peptide derivatives of mammalian MCH. The analogs can bind to the MCH receptor and, preferably, bring about signal transduction. MCH analogs have a variety of different uses including being used as a research tool and being used therapeutically.
    Type: Grant
    Filed: February 1, 2001
    Date of Patent: May 22, 2007
    Assignee: Merk & Co., Inc.
    Inventor: Maria A. Bednarek
  • Ghrelin analogs
    Patent number: 6967237
    Abstract: The present invention features truncated ghrelin analogs active at the GHS receptor. Ghrelin is a naturally occurring modified peptide. The analogs can bind to the GHS receptor and, preferably, bring about signal transduction. Ghrelin analogs have a variety of different uses including being used as a research tool and being used therapeutically.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: November 22, 2005
    Assignee: Merck & Co., Inc.
    Inventor: Maria A. Bednarek
  • Cyclic peptides as potent and selective melanocortin-4 receptors agonists
    Patent number: 6960646
    Abstract: Cyclic peptides of formula I are potent and selective agonists of melanocortin-4 receptors, and as such are useful research tool for the determination of the physiological roles of the MC-4 receptor, as well as for the diagnoses, treatment or prevention of disorders or diseases mediated through the MC-4 receptor.
    Type: Grant
    Filed: July 8, 2002
    Date of Patent: November 1, 2005
    Assignee: Merck & Co., Inc.
    Inventor: Maria A. Bednarek
  • Melanin-concentrating hormone analogs
    Publication number: 20050020492
    Abstract: The present invention features truncated hMCH analogs selectively active at MCH-1R over MCH-2R. Using amino acid numbering provided in hMCH, the featured analogs contain an X6 which is either a D-amino acid, 5-guanidinopropionic acid or its lower or higher homolog, or a derivative thereof; and a X10 which is either asparagine, glutamine, alanine, leucine, isoleucine, valine, norleucine, cyclohexylalanine, phenylalanine, (2?)-naphthylalanine, tyrosine, histidine, tryptophan, lysine, serine, threonine, methionine, or a derivative thereof.
    Type: Application
    Filed: January 6, 2003
    Publication date: January 27, 2005
    Inventor: Maria Bednarek
  • Melanin-concentrating hormone antagonists
    Publication number: 20040254338
    Abstract: The present invention features MCH antagonists active at the MCH-1R. The antagonists are optionally modified peptides able to inhibit the effect of MCH at MCH-1R. MCH antagonists have a variety of uses including being used as a research tool and being used to achieve a beneficial effect in a subject.
    Type: Application
    Filed: February 3, 2004
    Publication date: December 16, 2004
    Inventor: Maria A. Bednarek
  • Cyclic peptides as potent and selective melanocortin-4 receptors agonists
    Publication number: 20040171793
    Abstract: Cyclic peptides of formula I are potent and selective agonists of melanocortin-4 receptors, and as such are useful research tool for the determination of the physiological roles of the MC-4 receptor, as well as for the diagnoses, treatment or prevention of disorders or diseases mediated through the MC-4 receptor.
    Type: Application
    Filed: January 8, 2004
    Publication date: September 2, 2004
    Inventor: Maria A. Bednarek
  • Melanin-concentrating hormone analogs
    Publication number: 20040147432
    Abstract: The present invention features truncated MCH analogs active at the melanin concentrating hormone type 2 receptor (MCH-2R) and uses of such analogs. Truncated MCH analogs described herein include those active at MCH-2R and MCH-1R, and those selectively active at MCH-2R. MCH-2R analogs have a variety of different uses including being used as a research tool and being used therapeutically.
    Type: Application
    Filed: November 17, 2003
    Publication date: July 29, 2004
    Inventor: Maria Bednarek
  • Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
    Patent number: 6693165
    Abstract: Cyclic peptides of formula I are potent and selective antagonists of melanocortin-4 receptors, and as such are useful research tool for the determination of the physiological roles of the MC-4 receptor, as well as for the diagnosis, treatment or prevention of disorders or diseases mediated through the MC-4 receptor.
    Type: Grant
    Filed: January 16, 2001
    Date of Patent: February 17, 2004
    Assignee: Merck & Co., Inc.
    Inventor: Maria A. Bednarek
  • Gherlin analogs
    Publication number: 20030186844
    Abstract: The present invention features truncated ghrelin analogs active at the GHS receptor. Ghrelin is a naturally occurring modified peptide. The analogs can bind to the GHS receptor and, preferably, bring about signal transduction. Ghrelin analogs have a variety of different uses including being used as a research tool and being used therapeutically.
    Type: Application
    Filed: November 15, 2002
    Publication date: October 2, 2003
    Inventor: Maria A. Bednarek
  • Melanin-concentrating hormone analogs
    Publication number: 20030105278
    Abstract: The present invention features truncated MCH analogs active at the MCH receptor. The truncated MCH analogs are optionally modified peptide derivatives of mammalian MCH. The analogs can bind to the MCH receptor and, preferably, bring about signal transduction. MCH analogs have a variety of different uses including being used as a research tool and being used therapeutically.
    Type: Application
    Filed: July 31, 2002
    Publication date: June 5, 2003
    Inventor: Maria A. Bednarek
  • Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
    Publication number: 20020016291
    Abstract: Cyclic peptides of formula I are potent and selective antagonists of melanocortin-4 receptors, and as such are useful research tool for the determination of the physiological roles of the MC-4 receptor, as well as for the diagnosis, treatment or prevention of disorders or diseases mediated through the MC-4 receptor.
    Type: Application
    Filed: January 16, 2001
    Publication date: February 7, 2002
    Inventor: Maria A. Bednarek